Ertumaxomab
http://dbpedia.org/resource/Ertumaxomab an entity of type: Thing
إرتوماكسوماب هو جسم مضاد وحيد النسيلة مجانس (جرذي-فأري) طوّر لعلاج بعض أنواع الأورام. أوقفت التجارب السريرية عليه في مرحلتها الثانية لاستخدامه في علاج سرطان الثدي بعد النتائج التي تحققت في ترازتوزوماب.
rdf:langString
Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer. It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells. Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans. (So they could concentrate on their other product catumaxomab (trade name Removab).)
rdf:langString
L'ertumaxomab nome commerciale Rexomun, è un anticorpo monoclonale ibrido Topo/ratto, valutato in studi di fase II per il trattamento del tumore della mammella.Viene anche chiamato anticorpo tri-funzionale perché agisce collegando le cellule T, i macrofagi e le cellule cancerose insieme. Il target molecolare del farmaco è l'antigene HER2/neu e CD3
rdf:langString
rdf:langString
إرتوماكسوماب
rdf:langString
Ertumaxomab
rdf:langString
Ertumaxomab
xsd:integer
9042799
xsd:integer
949616828
rdf:langString
none
xsd:integer
509077
rdf:langString
none
rdf:langString
axo
rdf:langString
Rexomun
rdf:langString
mab
rdf:langString
L5L45YGP1O
rdf:langString
changed
xsd:integer
457120720
rdf:langString
إرتوماكسوماب هو جسم مضاد وحيد النسيلة مجانس (جرذي-فأري) طوّر لعلاج بعض أنواع الأورام. أوقفت التجارب السريرية عليه في مرحلتها الثانية لاستخدامه في علاج سرطان الثدي بعد النتائج التي تحققت في ترازتوزوماب.
rdf:langString
Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer. It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells. Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans. (So they could concentrate on their other product catumaxomab (trade name Removab).)
rdf:langString
L'ertumaxomab nome commerciale Rexomun, è un anticorpo monoclonale ibrido Topo/ratto, valutato in studi di fase II per il trattamento del tumore della mammella.Viene anche chiamato anticorpo tri-funzionale perché agisce collegando le cellule T, i macrofagi e le cellule cancerose insieme. Il target molecolare del farmaco è l'antigene HER2/neu e CD3
xsd:integer
3
xsd:nonNegativeInteger
2239
rdf:langString
Rexomun
xsd:string
509077-99-0
xsd:string
L5L45YGP1O